The "2nd User Meeting on Protein Arrays for Clinical Applications" took place at the BioMedizinZentrum Dortmund on November 16th, 2010. Invited by Protagen, a panel of 16 international speakers from renowned clinics, research institutions, and industry presented insights on the current and future developments of personalized medicines in autoimmune diseases, cancer, and neurodegenerative disorders. The program was rounded up with technology lectures on future trends in multiplex assays diagnostic applications including bioinformatic solutions and new regulations for medical devices.
Dr. Peter Schulz-Knappe, CSO of Protagen AG stated: "The relevance of autoantibody signatures for advanced diagnostic and therapeutic indications are becoming increasingly important and Protagen is well positioned with it's validated UNIarray® technology to serve the needs in this market segment. More than 70 attendants enjoyed the interdisciplinary atmosphere at the symposium and engaged in network discussions with experts from all relevant disciplines involved in personalized medicine and modern diagnostic assay platforms. A follow-up meeting is already planned for fall 2011.
Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition, UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.
Dr. Peter Schulz-Knappe, CSO of Protagen AG stated: "The relevance of autoantibody signatures for advanced diagnostic and therapeutic indications are becoming increasingly important and Protagen is well positioned with it's validated UNIarray® technology to serve the needs in this market segment. More than 70 attendants enjoyed the interdisciplinary atmosphere at the symposium and engaged in network discussions with experts from all relevant disciplines involved in personalized medicine and modern diagnostic assay platforms. A follow-up meeting is already planned for fall 2011.
Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition, UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.
